

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Nexium 40 mg gastro-resistant tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each gastro-resistant tablet contains 40 mg of esomeprazole (as magnesium trihydrate)

Excipient(s) with known effect:


Each gastro resistant tablet contains sucrose

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Gastro-resistant tablet

*Product imported from Greece.*

A pink, biconvex, film-coated tablet engraved 40 mg on one side and  on the other side.

## 4 CLINICAL PARTICULARS

As per PA2242/013/003

## 5 PHARMACOLOGICAL PROPERTIES

As per PA2242/013/003

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Glycerol monostearate 40-55,  
hypromellose,  
hypromellose,  
iron oxide (reddish-brown) (E 172),  
magnesium stearate,  
methacrylic acid ethyl acrylate copolymer (1:1) dispersion 30 per cent,  
microcrystalline cellulose,  
synthetic paraffin,  
macrogol 6000,  
polysorbate 80,  
crospovidone,  
sodium stearyl fumarate,  
sugar spheres (sucrose and maize starch),  
talc,  
titanium dioxide (E 171),  
triethyl citrate

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

28 September 2022

CRN00CZ90

Page 1 of 2

The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin

#### **6.4 Special precautions for storage**

Do not store above 30 °C.

Store in the original package (blister) in order to protect from moisture.

#### **6.5 Nature and contents of container**

Nexium is supplied in blister packs of 28 tablets.

#### **6.6 Special precautions for disposal and other handling**

No special requirements for disposal.

#### Administration through gastric tube

1. Put the tablet into an appropriate syringe and fill the syringe with approximately 25 ml water and approximately 5 ml air. For some tubes, dispersion in 50 ml water is needed to prevent the pellets from clogging the tube.
2. Immediately shake the syringe for approximately 2 minutes to disperse the tablet.
3. Hold the syringe with the tip up and check that the tip has not clogged.
4. Attach the syringe to the tube whilst maintaining the above position.
5. Shake the syringe and position it with the tip pointing down. Immediately inject 5–10 ml into the tube. Invert the syringe after injection and shake (the syringe must be held with the tip pointing up to avoid clogging of the tip).
6. Turn the syringe with the tip down and immediately inject another 5–10 ml into the tube. Repeat this procedure until the syringe is empty.
7. Fill the syringe with 25 ml of water and 5 ml of air and repeat step 5 if necessary to wash down any sediment left in the syringe. For some tubes, 50 ml water is needed.

### **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Originalis B.V.,  
Joop Geesinkweg 901,  
1114 AB Amsterdam-Duivendrecht,  
The Netherlands

### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA2306/025/002

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 23<sup>rd</sup> September 2022

### **10 DATE OF REVISION OF THE TEXT**